Open Collections

UBC Faculty Research and Publications

Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome Halyabar, Olha; Chang, Margaret H.; Schoettler, Michelle L.; Schwartz, Marc A.; Baris, Ezgi H.; Benson, Leslie A.; Biggs, Catherine M.; Gorman, Mark; Lehmann, Leslie; Lo, Mindy S.; Nigrovic, Peter A.; Platt, Craig D.; Priebe, Gregory P.; Rowe, Jared; Sundel, Robert P.; Surana, Neeraj K.; Weinacht, Katja G.; Mann, Alison; Yuen, Jenny C.; Meleedy-Rey, Patricia; Starmer, Amy; Banerjee, Taruna; Dedeoglu, Fatma; Degar, Barbara A.; Hazen, Melissa M.; Henderson, Lauren A.

Abstract

Background: Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) were historically thought to be distinct entities, often managed in isolation. In fact, these conditions are closely related. A collaborative approach, which incorporates expertise from subspecialties that previously treated HLH/MAS independently, is needed. We leveraged quality improvement (QI) techniques in the form of an Evidence-Based Guideline (EBG) to build consensus across disciplines on the diagnosis and treatment of HLH/MAS. Methods: A multidisciplinary work group was convened that met monthly to develop the HLH/MAS EBG. Literature review and expert opinion were used to develop a management strategy for HLH/MAS. The EBG was implemented, and quality metrics were selected to monitor outcomes. Results: An HLH/MAS clinical team was formed with representatives from subspecialties involved in the care of patients with HLH/MAS. Broad entry criteria for the HLH/MAS EBG were established and included fever and ferritin ≥500 ng/mL. The rheumatology team was identified as the “gate-keeper,” charged with overseeing the diagnostic evaluation recommended in the EBG. First-line medications were recommended based on the acuity of illness and risk of concurrent infection. Quality metrics to be tracked prospectively based on time to initiation of treatment and clinical response were selected. Conclusion: HLH/MAS are increasingly considered to be a spectrum of related conditions, and joint management across subspecialties could improve patient outcomes. Our experience in creating a multidisciplinary approach to HLH/MAS management can serve as a model for care at other institutions.

Item Metadata

Title
Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome
Creator
Halyabar, Olha; Chang, Margaret H.; Schoettler, Michelle L.; Schwartz, Marc A.; Baris, Ezgi H.; Benson, Leslie A.; Biggs, Catherine M.; Gorman, Mark; Lehmann, Leslie; Lo, Mindy S.; Nigrovic, Peter A.; Platt, Craig D.; Priebe, Gregory P.; Rowe, Jared; Sundel, Robert P.; Surana, Neeraj K.; Weinacht, Katja G.; Mann, Alison; Yuen, Jenny C.; Meleedy-Rey, Patricia; Starmer, Amy; Banerjee, Taruna; Dedeoglu, Fatma; Degar, Barbara A.; Hazen, Melissa M.; Henderson, Lauren A.
Contributor
Children's Hospital (Vancouver, B.C.)
Publisher
BioMed Central
Date Issued
2019-02-14
Description
Background: Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) were historically thought to be distinct entities, often managed in isolation. In fact, these conditions are closely related. A collaborative approach, which incorporates expertise from subspecialties that previously treated HLH/MAS independently, is needed. We leveraged quality improvement (QI) techniques in the form of an Evidence-Based Guideline (EBG) to build consensus across disciplines on the diagnosis and treatment of HLH/MAS. Methods: A multidisciplinary work group was convened that met monthly to develop the HLH/MAS EBG. Literature review and expert opinion were used to develop a management strategy for HLH/MAS. The EBG was implemented, and quality metrics were selected to monitor outcomes. Results: An HLH/MAS clinical team was formed with representatives from subspecialties involved in the care of patients with HLH/MAS. Broad entry criteria for the HLH/MAS EBG were established and included fever and ferritin ≥500 ng/mL. The rheumatology team was identified as the “gate-keeper,” charged with overseeing the diagnostic evaluation recommended in the EBG. First-line medications were recommended based on the acuity of illness and risk of concurrent infection. Quality metrics to be tracked prospectively based on time to initiation of treatment and clinical response were selected. Conclusion: HLH/MAS are increasingly considered to be a spectrum of related conditions, and joint management across subspecialties could improve patient outcomes. Our experience in creating a multidisciplinary approach to HLH/MAS management can serve as a model for care at other institutions.
Subject
Macrophage activation syndrome (MAS); Hemophagocytic lymphohistiocytosis (HLH); Quality improvement research; Evidence-based guideline
Genre
Article
Type
Text
Language
eng
Date Available
2019-02-14
Provider
Vancouver : University of British Columbia Library
Rights
Attribution 4.0 International (CC BY 4.0)
DOI
10.14288/1.0376447
URI
http://hdl.handle.net/2429/68366
Affiliation
Medicine, Faculty of; Other UBC; Non UBC; Pediatrics, Department of
Citation
Pediatric Rheumatology. 2019 Feb 14;17(1):7
Publisher DOI
10.1186/s12969-019-0309-6
Peer Review Status
Reviewed
Scholarly Level
Faculty
Copyright Holder
The Author(s).
Rights URI
http://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution 4.0 International (CC BY 4.0)